Comment on CMS-2026-1256-0002

Summary: SetPoint Medical expresses a mixed position on the proposal to repeal the alternative pathway for NTAP and TPT. They support repealing the pathway for 510(k)-cleared devices due to a lack of robust clinical evidence but oppose repealing it for PMA-approved devices, arguing that these products provide the necessary safety and effectiveness data for Medicare reimbursement.